Welcome to our dedicated page for Milestone Pharmaceuticals SEC filings (Ticker: MIST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Milestone Pharmaceuticals Inc. (MIST) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents are central to understanding how Milestone reports on its cardiovascular drug programs, financial position, and material corporate events.
For Milestone, current reports on Form 8-K are especially important. Recent 8-K filings describe key milestones such as U.S. Food and Drug Administration approval of CARDAMYST™ (etripamil) nasal spray for adult paroxysmal supraventricular tachycardia (PSVT), acceptance of the company’s response to a Complete Response Letter, new PDUFA target dates, equity offerings, amendments to royalty purchase agreements, and the filing or use of corporate presentations. These filings often incorporate press releases that discuss clinical data, regulatory status, and financing terms in more detail.
Investors can also use this page to locate periodic reports such as annual reports on Form 10-K and quarterly reports on Form 10-Q, which Milestone references in its news releases. Those documents typically include audited or reviewed financial statements, discussions of research and development and commercial expenses, and risk factor sections addressing uncertainties around regulatory approvals, clinical trials, capital resources, and market conditions.
In addition, Milestone’s capital-raising activities are documented through registration statements and related filings, along with 8-Ks that summarize underwriting agreements, warrant terms, and senior secured convertible notes. These materials explain how the company finances the development and commercialization of CARDAMYST and the broader etripamil program.
On Stock Titan, users can view these filings as they are made available from EDGAR and rely on AI-powered summaries to highlight the main points in lengthy documents, including 10-Ks, 10-Qs, and 8-Ks. The platform also makes it easier to identify items related to topics such as regulatory approvals, financing transactions, and updates on the PSVT and AFib-RVR programs, helping readers navigate Milestone’s disclosure record more efficiently.
Milestone Pharmaceuticals President and CEO Joseph Oliveto filed an amended insider report updating the terms of a previously disclosed stock option grant. The filing shows an employee stock option to purchase 679,000 common shares at an exercise price of $1.96 per share.
The amendment states that the exercise price on the initial filings was incorrectly stated and is now corrected. One-fourth of the option shares will vest on February 2, 2027, with one thirty-sixth of the remaining shares vesting each month afterward, as long as Oliveto continues to provide service.
Milestone Pharmaceuticals Inc. reported an amended insider transaction for its Chief Medical Officer. The officer received an employee stock option to buy 204,000 common shares at an exercise price of $1.96 per share, granted on February 2, 2026 and expiring on February 2, 2036.
The amendment corrects an initially misstated exercise price. One-fourth of the option shares vest on February 2, 2027, with one thirty-sixth of the remaining shares vesting monthly thereafter, as long as the officer continues providing services.
Milestone Pharmaceuticals Inc. reported an amended insider transaction for its Chief Operating Officer. The filing corrects the exercise price on previously reported employee stock options and confirms a grant of 204,000 options with an exercise price of $1.96 per common share.
The options expire on February 2, 2036. One-fourth of the shares underlying the option vest on February 2, 2027, and the remaining shares vest in equal monthly installments over the following 36 months, as long as the executive continues providing service through each vesting date.
Milestone Pharmaceuticals Inc. reported an amended insider transaction for its Chief Commercial Officer. On February 2, 2026, the officer received an employee stock option to purchase 204,000 common shares at an exercise price of $1.96 per share, correcting an exercise price that had been stated incorrectly in initial filings.
According to the vesting schedule, one-fourth of the option shares vest on February 2, 2027, with one thirty-sixth of the remaining shares vesting monthly thereafter, as long as the officer continues providing service. Following this grant, the officer beneficially owns 204,000 stock options, held directly.
Milestone Pharmaceuticals Inc. insider filing: the company’s CFO and EVP of Corporate Development reported an amended employee stock option grant. The filing corrects the exercise price for an option to buy 204,000 common shares at
Milestone Pharmaceuticals granted its Chief Commercial Officer, Lorenz Muller, new equity awards. On February 2, 2026, he received an employee stock option204,000 common shares at an exercise price of $1.97 per share. One-fourth of these option shares vest on February 2, 2027, and the remaining shares vest in equal monthly installments over the following thirty-six months, as long as he continues providing service.
He was also granted 136,000 restricted stock units on the same date, each representing the right to receive one common share. These RSUs vest in four equal installments on February 2 of each year from 2027 through 2030, again contingent on continued service. After these grants, he beneficially owns all 204,000 option awards and 136,000 RSUs directly.
Milestone Pharmaceuticals Inc. granted new equity awards to its CFO and EVP of Corporate Development, Amit Hasija. On February 2, 2026, he received an employee stock option covering 204,000 common shares at an exercise price of $1.97 per share, expiring on February 2, 2036. One-fourth of these option shares vest on February 2, 2027, with the remaining shares vesting monthly over the following 36 months, contingent on continued service. He also received 136,000 restricted stock units, each representing one common share. These RSUs vest in four equal annual installments on February 2 of 2027, 2028, 2029, and 2030, also subject to continued service.
Milestone Pharmaceuticals Inc. reported that its Chief Operating Officer, Jeffrey Edward Nelson, received new equity awards. On February 2, 2026, he was granted an option to buy 204,000 common shares at $1.97 per share and 136,000 restricted stock units.
One-fourth of the option vests on February 2, 2027, with the remaining shares vesting monthly over three years, contingent on continued service. The RSUs vest in four equal annual installments on February 2 of 2027, 2028, 2029, and 2030, also subject to continued service.
Milestone Pharmaceuticals Inc. reported new equity awards to Chief Medical Officer David Bharucha. On February 2, 2026, he received an employee stock option covering 204,000 common shares at an exercise price of $1.97 per share, expiring February 2, 2036.
One-fourth of the option vests on February 2, 2027, with the remaining shares vesting in equal monthly installments over the following 36 months, assuming continued service. He also received 136,000 restricted stock units, each representing one common share, vesting in four equal annual installments on February 2 of 2027, 2028, 2029 and 2030, subject to continued service.
Milestone Pharmaceuticals Inc. President and CEO Joseph Oliveto reported new equity awards. On February 2, 2026, he was granted an employee stock option for 679,000 common shares at an exercise price of $1.97 per share and a restricted stock unit award covering 453,000 common shares.
Both awards are held directly and vest over several years. The option vests 25% on February 2, 2027, with the remaining option shares vesting monthly over the following 36 months. The restricted stock units vest in four equal annual installments from February 2, 2027 through February 2, 2030, contingent on continued service.